A new monoclonal antibody is being granted approval in Europe as a preventative measure to protect against RSV infection in very young babies — those most at risk of contracting the virus — during their first RSV season.
November 4, 2022, 3:01 AMNatalie Berg, an infant who contracted RSV and was in an I.C.U. for four days, at their home in Mount Zion, Ill., Oct. 30, 2022.In what could signal the promise of progress to come for newborn infants at risk for RSV, a new monoclonal antibody is being granted approval in Europe as a preventative measure to protect against RSV infection in very young babies -- those most at risk of contracting the virus -- during their first RSV season.
Sanofi tells ABC News they and AstraZeneca have already submitted their clinical trial data to the FDA. They expect to finalize their submission to the FDA by the end of this year, with the hopes of it being approved and available by the fall/ winter of 2023/2024. A sampling of national CDC data shows RSV cases recorded for all ages are occurring more than twice as high at this point this year compared to last year, with more than twice as many cases per week, and likely leading towards more severe cases, especially in pediatric emergency departments and pediatric hospitalizations, which have limited resources to begin with, according to Chief Innovation Officer at Boston Children’s Hospital and ABC News Contributor, Dr. John Brownstein.
It is designed to keep RSV from being as serious as it can be in the population most vulnerable to severe infection -- newborns. Now, as the masks have come down, the infection rates are going up at even higher rates, and experts emphasize how COVID-19 has thrown the typical seasonality of our respiratory viral waves.There is also no vaccine for RSV yet, while there is, of course, for COVID and the flu.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New RSV vaccine given in pregnancy protects newborns from illness, Pfizer saysThe drugmaker Pfizer announced positive trial results for its RSV vaccine designed to protect newborns.
Read more »
‘Extremely satisfying’: Scientist’s insight powers new RSV vaccine for infantsAmid the surge of respiratory syncytial virus, Barney Graham—a former scientist at the U.S. National Institute of Allergy and Infectious Diseases—reflects on how his team’s work was key to the apparent success of Pfizer’s RSV vaccine and others.
Read more »
Rising RSV respiratory virus hits kids hard, fills pediatric wards in Greater ClevelandUH Rainbow and Children’s Hospital is seeing double the number of children with RSV in their emergency department, compared with a month ago. And MetroHealth has seen a 500% increase in the past month.
Read more »
GM Plans New EV Startup Business Model For EuropeGM has named Jaclyn McQuaid to lead its new startup division that will focus on electric cars and trucks in Europe.
Read more »
Zeekr The Hot New EV Startup In China, Entering Europe SoonFollowing in the footsteps of NIO and XPeng, Zeekr is a relatively new and hot EV startup from China. It was formed in March 2021 as a premium electric vehicle brand from Geely, one of
Read more »